India, June 2 -- Co-Diagnostics Inc. (CODX) and its joint venture CoSara Diagnostics Pvt. Ltd. announced progress in developing a PCR-based diagnostic test for Ebola virus, alongside enhancements to the Co-Dx PCR point-of-care platform.
Ebola virus disease is a severe, often fatal illness in humans, with outbreaks historically concentrated in sub-Saharan Africa. Rapid and accurate diagnostics are critical for containment, as early detection can significantly improve patient outcomes and reduce transmission.
The companies reported that development of the Ebola PCR assay is advancing under CoSara's manufacturing capabilities in India, with plans to support regulatory submissions and eventual commercialization. The test is designed to delive...